Pharmacy 483: Steve Riddle, BS Pharm, BCPS QI and Medication Utilization Lead HMC Pharmacy February 22, 2005 Quality Improvement in Pharmacy.

Slides:



Advertisements
Similar presentations
Common/shared responsibilities between jobs.
Advertisements

Management of Drug Formulary Dimitry Gotlinsky Western University Managed Care Clerkship ProPharma Pharmaceutical Consultants, Inc. 06/16/06.
Medication Management
Quality Improvement Program 28 TAC §10.22 Workers’ Compensation Health Care Networks.
Acute Myocardial Infarction (AMI) JCAHO Core Measure Project Loyola University Medical Center Team Members: K. McLean MD, M. Morrow MSN, J. Cochran BSN,
Drug appropriateness criteria: potential for indications creep Amy Lodolce, PharmD, BCPS Mike Koronkowski, PharmD.
Performance Improvement Leadership Develop Program
Disease State Management The Pharmacist’s Role
MEDICINES SELECTION & FORMULARY MANAGEMENT
Drug Utilization Review (DUR)
Hospital Pharmacy Payam Parchamazad, PharmD Staff Pharmacist
Medication Therapy Management Linda Mach, PharmD Bartell Drugs Community Practice Resident February 26, 2010.
Documentation for Acute Care
Pharmacy 483 Outcomes & Cost Management in Pharmacy Practice Janet Kelly, Pharm.D., BC-ADM February 22, 2005.
Clinical Pharmacy Basma Y. Kentab MSc..
340B Implementation: An Opportunity for Improved Health Outcomes in Communities Todd D. Sorensen, Pharm.D. Associate Professor University of Minnesota.
Clinical pharmacy Dr. Mohammed Al-Rekabi Lecture One First Semester.
Pharmacy and Therapeutics Committee
QI and DUE in Pharmacy Practice Pharmacy 483: QI and DUE in Pharmacy Practice Steve Riddle, BS Pharm, BCPS QI and Medication Utilization Lead HMC Pharmacy.
2015 National Patient Safety Goals and the Older Adult Julie Pope Nurs 4292 Spring I Columbus State University.
Pharmacy Services.
 Definitions  Goals of automation in pharmacy  Advantages/disadvantages of automation  Application of automation to the medication use process  Clinical.
Continuous Quality Improvement Drug Utilization Evaluation.
Why are we learning this? How scientific knowledge (pharmacology, therapeutics) and clinical skills (measuring blood pressure, glucoses, drug information)
The Emergency Pharmacist (EPh): A Safety Measure in Emergency Medicine Supported by The Agency for Healthcare Research and Quality, Partnerships in Patient.
Basma Y. Kentab MSc.. 1. Define ambulatory care 2. Describe the value of ambulatory care practices 3. Explore pharmacy services in some ambulatory care.
Antimicrobial Stewardship St. Mary’s Hospital Infection Control Committee.
In Which Areas Have Clinical Pharmacists Been the Most Successful in Patient Care ? Hospital inpatient unit (wards) –Therapeutic drug monitoring –Anticoagulation.
The Value of Medication Therapy Management Services.
LDL Program Medical Management Philip E. Johnston, Pharm.D.
ACUTE MYOCARDIAL INFARCTION Team Membership Clinical Departments: Cardiology, Cardiovascular Surgery, Emergency Medical Services Hospital Departments:
1 EFFECT STUDY 2 EFFECT STUDY  Set national cardiac care benchmarks for hospitals to work towards 
Brooklyn College Spring 2003 February 18, 2003 Gene Shagas Student, CIS 763 Quality Management in Health Care.
Clinical Pharmacy Part 2
For Pain or Not for Pain: Methadone Madness
Compliance with clinical practice guidelines for the treatment and optimization of therapy in heart failure patients in outpatient medicine clinics MaryAnn.
Acute Myocardial Infarction (Heart Attack) Committee Membership: B. Majcher, APRN, C. Mulhall, APRN, K. McLean, MD, M. Jarotkiewicz RRT, MS, Administrative.
Social Pharmacy Lecture no. 6 Rational use of drugs Dr. Padma GM Rao
Put Prevention Into Practice. Understand the PPIP Program What is Put Prevention Into Practice (PPIP)? What is Put Prevention Into Practice (PPIP)? Why.
ASPECTS AFFECTING THE HOSPITAL OPERATION Financial Financial Operational Operational Administrative Administrative Clinical Clinical Safety Safety.
Community Acquired Pneumonia in the Emergency Department (ED) Emergency Department Nurses & Physicians Dr. Mark Cichon, Director; Bridget Gaughan, Manager.
Pharmacy 483 Outcomes & Cost Management in Pharmacy Practice Janet Kelly, Pharm.D., BC-ADM February 24, 2004.
Update and Clarifications Regarding Local Pharmaceutical Assistance Programs Susan Robilotto, D.O. Clinical Consultant/ Medical Officer Department of Health.
6/04 CRUSADE: A National Quality Improvement Initiative C an R apid Risk Stratification of U nstable Angina Patients S uppress AD verse Outcomes with E.
Acute Myocardial Infarction (Heart Attack) Committee Membership: B. Majcher, APRN, C. Mulhall, APRN, K. McLean, MD, M. Jarotkiewicz MBA, M. Morrow, RN,
Introduction.
MEDICATION MANAGEMENT P&T COMMITTEE AND FORMULARY MANAGEMENT EMTENAN ALHARBI, Msc CLINICAL PHARMACIST.
Acute Myocardial Infarction February 8, 2006.
Drug Formulary Development & Management
Technology, Information Systems and Reporting in Pharmacy Benefit Management Presentation Developed for the Academy of Managed Care Pharmacy Updated: February.
Pharmacist Opportunities Within a Pharmacy Benefit Manager Presentation Developed for the Academy of Managed Care Pharmacy Updated: February 2015.
Presentation Developed for the Academy of Managed Care Pharmacy
Medication Therapy Management Part D Programs Presentation Developed for the Academy of Managed Care Pharmacy Updated: February 2014.
 Pharmaceutical Care is a patient-centered, outcomes oriented pharmacy practice that requires the pharmacist to work in concert with the patient and.
Acute Myocardial Infarction Committee Membership : K. McLean, MD, M. Jarotkiewicz MBA, Administrative Director Cardiovascular Service Line, Mary Morrow,
Private and confidential Community Pharmacy Future Four-or-more medicines support service Update on progress and next steps Approved18 th June 2012 This.
Clinical Decision Support Implementation Victoria Ferguson, COO - Program Manager Christopher Taylor, CIO – Business Owner Monica Kaileh, CMIO – Steering.
Drug Utilization Review & Drug Utilization Evaluation: An Overview
Drug Utilization Review & Drug Utilization Evaluation: An Overview
Introduction to Clinical Pharmacy
Nursing Process in Pharmacology
Hospital Antibiotic Stewardship Programs
Provider and Member Education in Managed Care Pharmacy
Pharmacy practice experience I
Drug Utilization Review & Drug Utilization Evaluation: An Overview
Pharmacy practice and the healthcare system Ola Ali Nassr
Drug Utilization Review & Drug Utilization Evaluation: An Overview
Drug Formulary Development & Management
Many post-MI patients are not receiving optimal therapy
Presentation transcript:

Pharmacy 483: Steve Riddle, BS Pharm, BCPS QI and Medication Utilization Lead HMC Pharmacy February 22, 2005 Quality Improvement in Pharmacy

Goals of Presentation Increase understanding and awareness of the nature quality improvement and the basic processes involved. Gain knowledge regarding the role of the pharmacists in quality improvement. Learn about Drug Use Evaluation (DUE) and the value it can provide.

How do we assess quality? Quality Assurance (QA): any systematic process of checking to see whether a product or service is meeting specified requirements Quality Improvement (QI) –Focus is on improvement of product or service or process Continuous Quality Improvement (CQI) –not typically just one way to do something –because things are "done right the first time" does not mean they cannot be done better.

Why do we need QI in pharmacy or in healthcare Provide the right care to each and every patient –The right test and assessments –Most effective treatments –The safest therapies (risk vs benefit) Responsible use of resources –Cost Effectiveness: “Best bang for the buck”

Acute Myocardial Infarction “Heart Attack” What should be done for this patient?

What are the goals in treating this AMI patient? Procedures: PTCA (Angioplasty) Labs and Diagnostics: ECG, Echo, EF Drug Therapy: ASA, ACEI, Beta-blockers, Statins, Thrombolytics Messages: Healthy Lifestyle, Diet, Exercise, Stop Smoking

How are these goals determined? Clinical Guidelines per Professional Org –American Heart Association (AHA) –American College of Cardiology (ACC) –Local Institutional Groups (UW Med Cardiology) Oversight & Quality Organizations –Joint Commission for the Accreditation of Healthcare Organizations (JCAHO) –Centers for Medicare & Medicaid Services (CMS) –Association for Healthcare Research & Quality (AHRQ)

How do we evaluate performance? DATA DATA DATA …Establish “baseline” data information Collect data from treated patients Real-time or retrospective Compare data to… Institutional goals “Benchmarks” (other institutions or natl. performance)

HMC Baseline Rates for AMI Treatment Report from 10/2000, UHC Benchmarks ASABeta blockerACEIStatinSmoking Percent of Patients Cessation

Identify areas in need of improvement… Eliminate Quality Problems: Improve use of most appropriate agent Remove unsafe agents Reducing Costs… while maintaining or improving quality Generic product use Therapeutic substitution Drug purchasing contracts and put solutions into practice!

AMI Treatment: QI Example Optimize Clinical Outcomes Efficient Use Of Resources Disease-focused QI (example: treat AMI with ACE Inhibitors) Goals

AMI Treatment: Why are indicated drugs under utilized? ProblemsSolutions Provider Knowledge Inconsistent Prescribing Prescribing aids not used Complex processes  education/awareness of providers 1. Simplify processes  order sets, clinical pathways 2. Designate specific responsibilities 3. Add Clinical Care Coordinator or pharmacist to clinical team

Did it work? Check that data!

HMC Rates for Secondary Prevention in AMI Data from HMC Dsch Diagnosis Coding for AMI and CIS reviews ASABeta blockerACEIStatinSmoking Percent of Patients Cessation

QI Example #2: The DUE Optimize Clinical Outcomes Efficient Use Of Resources Disease-focused QI (example: treat AMI with ACE Inhibitors) Drug-focused QI (example: use most cost- effective ACEI) Goals

Drug Use Evaluation (DUE) Definition: Authorized, structured, ongoing review of practitioner prescribing, pharmacist dispensing and patient use of medications. Purpose: To ensure drugs are used appropriately, safely, and effectively to –Improve patient care –Lower the overall cost of care –Foster more efficient use of health care resources Process –Comprehensive review of medication use data –Identify patterns of prescribing

Examples of DUE Targets Therapeutic appropriateness Appropriate generic or ‘first-line agents’ utilization Inappropriate dose and/or duration Over and underutilization Compliance with polices/guidelines

Angiotensin Converting Enzyme Inhibitor (ACEI) Class Cost Safety Effectiveness -Generics vs brand -Reimbursement No major adverse effect differences Unique indications Captopril Enalapril Lisinopril Ramipril

DUE: Ramipril Restrictions: –Limited Indications: HOPE Criteria –Cost: Trade name vs. generic alternatives Appropriate Use –Chart reviews of users –Compare actual use to restriction criteria –Percent compliance rate Assessment

Ramipril DUE Results Overall, a 82.5% compliance rate for appropriate use. Of the 6 patients not meeting the HOPE criteria for ramipril use: -3 had only 1 identified risk factor (hypertension). -3 were eligible for treatment with 1 st –line formulary agents. # of patients receiving ramipril # of patients meeting HOPE criteria # of patients not meeting criteria Total40336 HMC34285 UWMC651

Pharmacist Role in QI Collaborate in development of practice guidelines – Committee involvement – Standing order and clinical pathway development Influence prescribing patterns – Daily rounding or clinic interactions – Conduct educational programs for residents – Provide feedback to prescribers around specific drugs – “Academic-detailing” Perform direct patient care roles – Anticoagulation service – Collaborative disease management protocols – Patient education programs

Specific Pharmacy Roles in QI (ie. Janet and myself) Develop, implement and oversee institutional and pharmacy department quality goals Work with administration, providers and pharmacy staff to assure goals are being met Provide data and feedback to stakeholders

QUESTIONS?